TherapeuticsMD (TXMD) Price to Sales (2011 - 2026)

TherapeuticsMD (TXMD) has reported Price to Sales for 16 consecutive years, with 29.43 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales rose 108.71% year-over-year to 29.43; the trailing twelve-month figure through Jun 2026 stood at 7.82 (up 49.09% YoY), and the FY2025 full-year result was 6.24, up 10.85% from the prior year.
• Price to Sales eased to 29.43 in Q2 2026 per TXMD's latest filing, from 32.29 in the prior quarter.
• Across five years, Price to Sales topped out at 602.58 in Q3 2023 and bottomed at 0.77 in Q4 2022.
• Historically, Price to Sales has averaged 103.46 across 5 years, with a median of 43.34 in 2023.
• The sharpest annual moves came in 2022 and 2023: Price to Sales sank 99.81% in 2022, then surged 6574.95% in 2023.
• Over 5 years, Price to Sales stood at 0.77 in 2022, then soared by 6574.95% to 51.69 in 2023, then sank by 71.23% to 14.87 in 2024, then jumped by 42.08% to 21.13 in 2025, then jumped by 39.33% to 29.43 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 29.43, 32.29, and 21.13 for Q2 2026, Q1 2026, and Q4 2025 respectively.